Clinical Trial Update: Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients [Phase 3]

View source ↗

Summary

Phase 3 multicenter trial evaluating maintenance monotherapy with olaparib in platinum-sensitive relapsed non-germline BRCA mutated ovarian cancer. Results have…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Germline BRCA Mutated Ovarian Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-10-11